Valneva reports H1 2026 product sales €64.0M, net loss €63.3M
Valneva reports H1 2026 total product sales of €64.0 million, down from €91.0 million YoY, and a net loss widening to €63.3 million from €20.8 million YoY, while reaffirming full-year guidance of €135–150 million.
Total product sales of €64.0 million In-line with expectations; full-year guidance of €135 -150 million reaffirmed Solid cash position of €121.5 million as of end June 2026 Reflects disciplined cash management and proceeds from the recent reserved offering1 Restructuring program implemented with positive P&L and cash flow impacts expected in the second half of the year and beyond Regulatory decisions for Lyme disease vaccine candidate expected in the next twelve months2 Pfizer remains optimistic about obtaining registration for the vaccine candidate3